Trial · NCT03753919
Results by group75
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 75
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-free Survival Rate at 6 Months | COHORT 1: Advanced, Radioiodine-refractory Differentiated Thyroid Carcinoma (DTC) | 32.4 | 95% Confidence Interval 20.4 to 51.6 | percentage of patients | |
| Progression-free Survival Rate at 6 Months | COHORT 2: Advanced Medullary Thyroid Carcinoma (MTC) | 40.9 | 95% Confidence Interval 26.3 to 63.6 | percentage of patients | |
| Progression-free Survival Rate at 6 Months | COHORT 3: Advanced Anaplastic Thyroid Carcinoma (ATC) | 33.3 | 95% Confidence Interval 15.0 to 74.2 | percentage of patients | |
| Overall Survival Rate at 6 Months | COHORT 1: Advanced, Radioiodine-refractory Differentiated Thyroid Carcinoma (DTC) | 70.3 | 95% Confidence Interval 56.7 to 86.7 | percentage of patients | |
| Overall Survival Rate at 6 Months | COHORT 2: Advanced Medullary Thyroid Carcinoma (MTC) | 96.6 | 95% Confidence Interval 90.1 to 100 | percentage of patients | |
| Overall Survival Rate at 6 Months | COHORT 3: Advanced Anaplastic Thyroid Carcinoma (ATC) | 65.6 | 95% Confidence Interval 43.2 to 99.8 | percentage of patients | |
| Overall Survival, Median | COHORT 1: Advanced, Radioiodine-refractory Differentiated Thyroid Carcinoma (DTC) | 13.8 | 95% Confidence Interval 9.4 to 32.8 | months | |
| Overall Survival, Median | COHORT 2: Advanced Medullary Thyroid Carcinoma (MTC) | 35.5 | 95% Confidence Interval 30.1 to NA | months | |
| Overall Survival, Median | COHORT 3: Advanced Anaplastic Thyroid Carcinoma (ATC) | 13.8 | 95% Confidence Interval 5.7 to NA | months | |
| Overall Survival Rate at 18 Months | COHORT 1: Advanced, Radioiodine-refractory Differentiated Thyroid Carcinoma (DTC) | 41.5 | 95% Confidence Interval 28.0 to 61.4 | percentage of patients | |
| Overall Survival Rate at 18 Months | COHORT 2: Advanced Medullary Thyroid Carcinoma (MTC) | 78.8 | 95% Confidence Interval 65.3 to 97.5 | percentage of patients | |
| Overall Survival Rate at 18 Months | COHORT 3: Advanced Anaplastic Thyroid Carcinoma (ATC) | 46.9 | 95% Confidence Interval 25.0 to 87.9 | percentage of patients | |
| Progression-free Survival (PFS), Median | COHORT 1: Advanced, Radioiodine-refractory Differentiated Thyroid Carcinoma (DTC) | 3.7 | 95% Confidence Interval 2.7 to 6.5 | months | |
| Progression-free Survival (PFS), Median | COHORT 2: Advanced Medullary Thyroid Carcinoma (MTC) | 5.3 | 95% Confidence Interval 2.8 to 23.2 | months | |
| Progression-free Survival (PFS), Median | COHORT 3: Advanced Anaplastic Thyroid Carcinoma (ATC) | 3.6 | 95% Confidence Interval 2.2 to NA | months | |
| Progression-free Survival Rate at 18 Months | COHORT 1: Advanced, Radioiodine-refractory Differentiated Thyroid Carcinoma (DTC) | 6.0 | 95% Confidence Interval 1.6 to 22.6 | percentage of patients | |
| Progression-free Survival Rate at 18 Months | COHORT 2: Advanced Medullary Thyroid Carcinoma (MTC) | 26.5 | 95% Confidence Interval 13.6 to 51.6 | percentage of patients | |
| Progression-free Survival Rate at 18 Months | COHORT 3: Advanced Anaplastic Thyroid Carcinoma (ATC) | 8.3 | 95% Confidence Interval 1.3 to 54.4 | percentage of patients | |
| Overall Response Rate (ORR) | COHORT 1: Advanced, Radioiodine-refractory Differentiated Thyroid Carcinoma (DTC) | 8 | percentage of patients | ||
| Overall Response Rate (ORR) | COHORT 2: Advanced Medullary Thyroid Carcinoma (MTC) | 10 | percentage of patients |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03753919/results